Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...
centerforbiosimilars22m
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...